Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA).
cholesterol
hyperlipidaemia
hypoxia
obesity
sleep apnoea
Journal
Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
2
7
2019
medline:
26
5
2020
entrez:
2
7
2019
Statut:
ppublish
Résumé
Obstructive sleep apnoea (OSA) and hyperlipidaemia are independent risk factors for cardiovascular disease. This study investigates the association between OSA and prevalence of hyperlipidaemia in patients of the European Sleep Apnea Database (ESADA) cohort. The cross-sectional analysis included 11 892 patients (age 51.9 ± 12.5 years, 70% male, body mass index (BMI) 31.3 ± 6.6 kg/m Hyperlipidaemia prevalence increased from 15.1% in subjects without OSA to 26.1% in those with severe OSA, P < 0.001. Corresponding numbers in patients with diabetes were 8.5% and 41.5%, P < 0.001. Compared with ODI quartile I, patients in ODI quartiles II-IV had an adjusted OR (95% CI) of 1.33 (1.15-1.55), 1.37 (1.17-1.61) and 1.33 (1.12-1.58) (P < 0.001), respectively, for hyperlipidaemia. Obesity was defined as a significant risk factor for hyperlipidaemia. Subgroups of OSA patients with cardio-metabolic comorbidities demonstrated higher prevalence of HL. In addition, differences in hyperlipidaemia prevalence were reported in European geographical regions with the highest prevalence in Central Europe. Obstructive sleep apnoea, in particular intermittent hypoxia, was independently associated with the prevalence of hyperlipidaemia diagnosis.
Sections du résumé
BACKGROUND AND OBJECTIVE
Obstructive sleep apnoea (OSA) and hyperlipidaemia are independent risk factors for cardiovascular disease. This study investigates the association between OSA and prevalence of hyperlipidaemia in patients of the European Sleep Apnea Database (ESADA) cohort.
METHODS
The cross-sectional analysis included 11 892 patients (age 51.9 ± 12.5 years, 70% male, body mass index (BMI) 31.3 ± 6.6 kg/m
RESULTS
Hyperlipidaemia prevalence increased from 15.1% in subjects without OSA to 26.1% in those with severe OSA, P < 0.001. Corresponding numbers in patients with diabetes were 8.5% and 41.5%, P < 0.001. Compared with ODI quartile I, patients in ODI quartiles II-IV had an adjusted OR (95% CI) of 1.33 (1.15-1.55), 1.37 (1.17-1.61) and 1.33 (1.12-1.58) (P < 0.001), respectively, for hyperlipidaemia. Obesity was defined as a significant risk factor for hyperlipidaemia. Subgroups of OSA patients with cardio-metabolic comorbidities demonstrated higher prevalence of HL. In addition, differences in hyperlipidaemia prevalence were reported in European geographical regions with the highest prevalence in Central Europe.
CONCLUSION
Obstructive sleep apnoea, in particular intermittent hypoxia, was independently associated with the prevalence of hyperlipidaemia diagnosis.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
676-688Investigateurs
P Steiropoulos
(P)
J Verbraecken
(J)
E Petiet
(E)
G Trakada
(G)
J M Montserrat
(JM)
I Fietze
(I)
T Penzel
(T)
D Rodenstein
(D)
J F Masa
(JF)
S Schiza
(S)
B Kent
(B)
W T McNicholas
(WT)
S Ryan
(S)
R L Riha
(RL)
J A Kvamme
(JA)
R Schulz
(R)
D Zou
(D)
J L Pépin
(JL)
P Levy
(P)
S Bailly
(S)
L Lavie
(L)
P Lavie
(P)
M S Tasbakan
(MS)
G Varoneckas
(G)
P Joppa
(P)
R Tkacova
(R)
F Barbé
(F)
C Lombardi
(C)
G Parati
(G)
M Drummond
(M)
M van Zeller
(M)
O Marrone
(O)
M Petitjean
(M)
M Pretl
(M)
A Vitols
(A)
Z Dogas
(Z)
T Galic
(T)
U Anttalainen
(U)
T Saaresranta
(T)
R Plywaczewski
(R)
P Bielicki
(P)
Informations de copyright
© 2019 The Association for the Publication of the Journal of Internal Medicine.
Références
Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: THE HypnoLaus study. Lancet Respir Med 2015; 3: 310-8.
Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population-A review on the epidemiology of sleep apnea. J Thorac Dis 2015; 7: 1311-22.
Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009; 373: 82-93.
Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-53.
Kent BD, Grote L, Ryan S, et al. Diabetes mellitus prevalence and control in sleep-disordered breathing. Chest 2014; 146: 982-90.
Murphy AM, Thomas A, Crinion SJ, et al. Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. Eur Respir J 2017; 49: 1601731.
Li J, Savransky V, Nanayakkara A, Smith PL, O'Donnell CP, Polotsky VY. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia 5. J Appl Physiol 2007; 102: 557-63.
Drager LF, Polotsky VY, O'Donnell CP, Cravo SL, Lorenzi-Filho G, Machado BH. Translational approaches to understanding metabolic dysfunction and cardiovascular consequences of obstructive sleep apnea. Am J Physiol - Hear Circ Physiol 2015; 309: H1101-11.
Jun J, Polotsky VY. Metabolic consequences of sleep-disordered breathing. ILAR J 2009; 50: 289-306.
Newman AB, Nieto FJ, Guidry U, et al. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001; 154: 50-9.
Drager LF, Jun J, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes 2010; 17: 161-5.
Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010; 7: 677-85.
Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of sleep apnea. Physiol Rev 2010; 90: 47-112.
Gündüz C, Basoglu OK, Hedner J, et al. Obstructive sleep apnoea independently predicts lipid levels: Data from the European Sleep Apnea Database. Respirology 2018; 23: 1180-9.
Adedayo AM, Olafiranye O, Smith D, et al. Obstructive sleep apnea and dyslipidemia: Evidence and underlying mechanism. Sleep Breath 2014; 18: 13-8.
Hedner J, Grote L, Bonsignore M, et al. The European Sleep Apnoea Database (ESADA): Report from 22 European sleep laboratories. Eur Respir J 2011; 38: 635-42.
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-5.
NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on. 01-3670. 2001; 285: 40.
Iber C, Ancoli-Israeli SCA, Quan S. The AASM Manual for the Scoring Of Sleep And Associated Events: Rules, Terminology And Technical Specifications, 1st ed. Westchester, IL: American Academy of Sleep Medicine, 2007.
Escourrou P, Grote L, Penzel T, et al. The diagnostic method has a strong influence on classification of obstructive sleep apnea. J Sleep Res 2015; 24: 730-8.
Kent BD, Grote L, Bonsignore M et al. Sleep apnoea severity independently predicts glycaemic health in nondiabetic subjects: the ESADA study. Eur Respir J 2014; 44:130-9.
Börgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J Off J Eur Soc Clin Respir Physiol 2006; 27: 121-7.
Lam JCM, Lam B, Lam C-L, et al. Obstructive sleep apnea and the metabolic syndrome in community-based Chinese adults in Hong Kong. Respir Med 2006; 100: 980-7.
Togeiro SM, Carneiro G, Ribeiro Filho FF, et al. Consequences of obstructive sleep apnea on metabolic profile: A population-based survey. Obesity 2013; 21: 847-51.
Chou Y-T, Chuang L-P, Li H-Y, et al. Hyperlipidaemia in patients with sleep-related breathing disorders: prevalence & risk factors. Indian J Med Res 2010; 131: 121-5.
Kono M, Tatsumi K, Saibara T, et al. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007; 131: 1387-92.
Guan J, Yi H, Zou J, et al. Distinct severity stages of obstructive sleep apnoea are correlated with unique dyslipidaemia: Large-scale observational Study. Thorax 2016; 71: 347-55.
McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: A matched controlled study. Am J Respir Crit Care Med 2007; 175: 190-5.
Gruber A, Horwood F, Sithole J, Ali NJ, Idris I. Metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol 2006; 7: 1-7.
Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003; 91: 891-4.
Bays H. Adiposopathy, “sick fat”, Ockham’s razor, and resolution of the obesity paradox. Curr Atheroscler Rep 2014; 16: 409.
Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2006; 2: 367-73.
Lin M-T, Lin H-H, Lee P-L, et al. Beneficial effect of continuous positive airway pressure on lipid profiles in obstructive sleep apnea: a meta-analysis. Sleep Breath 2015; 19: 809-17.
Anon. WHO | Global Health Observatory data. WHO 2015.
Nichols M, Townsend N, Luengo-Fernandez R, et al. European cardiovascular disease statistics 2012. 2012.
Geovanini GR, Wang R, Weng J, et al. Association between obstructive sleep apnea and cardiovascular risk factors-variation by age, sex and race: the multi-ethnic study of Atherosclerosis (MESA). Ann Am Thorac Soc 2018; 15: 970-977. AnnalsATS.201802-121OC.
Simpson L, McArdle N, Eastwood PR, et al. Physical inactivity is associated with moderate-severe obstructive sleep apnea. J Clin Sleep Med 2015; 11: 1091-1099A.